COO Surges As Cooper Companies Extends Earnings Beat Streak

The Cooper Companies Inc. stocks have been trading up by 8.47 percent amid bullish analyst upgrades and strong earnings outlook.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading COO

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Record Q2 2026 revenue of $1.08B and non‑GAAP EPS of $1.21 both beat estimates, marking The Cooper Companies Inc.’s tenth straight earnings beat and reinforcing execution strength.
A $271.6M litigation charge tied to CooperSurgical’s 2023 fertility media recall pushed GAAP EPS to -$0.40, but most related claims are now agreed in principle, easing a major risk overhang.
Management reaffirmed 2026 non‑GAAP EPS guidance of $4.58–$4.66, slightly trimmed revenue to $4.29–$4.32B, and reiterated a >$2.2B free cash flow target for 2026–2028, supporting medium‑term cash generation.
Shares of COO jumped roughly 7–8.6% to the mid‑$60s, briefly leading the S&P 500 after the beat and guidance update, signaling a strong sentiment reset and short‑term momentum.
Multiple brokers cut price targets into an $85–$95 range but kept Buy/Outperform views, citing de‑risked guidance, operating leverage, strategic flexibility, and a potential CooperSurgical divestiture toward a cleaner CooperVision story.

Weekly Update Jun 01 – Jun 05, 2026: On Saturday, June 06, 2026 The Cooper Companies Inc. stock [NASDAQ: COO] is trending up by 8.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Cooper Companies sits in the upper tier of global medtech growth stories, driven by structurally attractive contact lenses and a recovering surgical franchise. Revenue growth of 7–11% over 3–5 years, 65% gross margins, and ~27% EBITDA margins position COO above the broader Healthcare and Med Tech averages, though GAAP ROIC (4–6%) remains subpar due to goodwill and legal charges. Balance sheet leverage is conservative (D/E 0.3, interest coverage 11.7x), and FCF conversion is strong, with Q2 free cash flow of $96M despite litigation-related noise.

Technically, COO has shifted from a base-building phase into a short-term uptrend following the earnings gap. The weekly sequence from ~$59 to ~$67, with a large expansion bar on elevated volume, confirms buyers in control. The key actionable level is the post-gap support zone at $64–65; above this, momentum traders can lean long with upside toward the mid‑70s. A decisive break back below $64 on heavy volume would invalidate the bullish setup and argue for a retest of the high‑50s.

More Breaking News

Fundamentally and strategically, COO remains a high-quality compounder versus Healthcare and Med Equipment peers, with superior organic growth, consistent non-GAAP EPS beats, and a clear FCF roadmap (> $2.2B over 2026–2028). The resolution of most CooperSurgical litigation and potential CSI divestiture de-risk the story and sharpen the CooperVision focus, offsetting trimmed guidance and APAC softness. With Street targets clustered in the mid‑80s, I see fair value at $80–85, near-term support at $64 and resistance around $75.

Quick Financial Overview

The Cooper Companies Inc. put up solid headline numbers in Q2 2026. Revenue climbed to about $1.08B, up 8% year over year and 5% organically, while non‑GAAP EPS rose 26% to $1.21, above consensus. Both CooperVision and CooperSurgical segments grew 8%, and non‑GAAP operating margin hit 27%, which lines up with the strong 65.4% gross margin and mid‑teens EBIT margin in the ratio set. On a non‑GAAP basis, COO is acting like a steady compounder.

Under the surface, GAAP EPS of -$0.40 reflects the $271.6M litigation hit from the 2023 fertility media recall. That aligns with the income statement’s negative net income and operating income, but the cash flow statement tells a different story: operating cash flow of about $182.8M and free cash flow near $96.4M in the quarter. With total debt to equity around 0.3 and interest coverage near 11.7, The Cooper Companies Inc. carries manageable leverage and healthy coverage, even with the non‑cash legal charge.

On valuation, COO trades at a P/E near 39.7 and price‑to‑sales around 3.8, leaving room if management hits its multi‑year >$2.2B free cash flow goal. Weekly price action shows a sharp shift: the stock pushed from roughly $59–$60 early in the week to a high just under $68 after earnings, closing near $67.27. Intraday, the 5‑minute candle around the move shows a surge from the mid‑$65s to the high‑$67s, a clear bullish impulse. For short‑term traders, that confirms a fresh momentum leg off a prior base in the low $60s.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!